# NantKwest, Inc. (NK)

Source: https://www.quantisnow.com/company/NK
Generated: 2026-11-11T20:25:13.086Z

- Ticker: NK
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2015

## Latest NK news and filings

- 2021-06-23 20:05 UTC [Leadership Update] [Motus GI Appoints Experienced Financial Biotech Executive, Sonja Nelson, to its Board of Directors and as Chair of Audit Committee](https://www.quantisnow.com/insight/motus-gi-appoints-experienced-financial-biotech-executive-sonja-nelson-to-1122213)
- 2021-03-17 21:24 UTC [SEC Form 8-K] [SEC Form 8-K filed by NantKwest, Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-nantkwest-inc-523626)
- 2021-03-12 19:59 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-506503)
- 2021-03-12 02:50 UTC [SEC Form 3] [SEC Form 3 filed by Christobel Selecky](https://www.quantisnow.com/insight/sec-form-3-filed-by-christobel-selecky-503152)
- 2021-03-12 02:49 UTC [SEC Form 3] [SEC Form 3 filed by C. David Sachs](https://www.quantisnow.com/insight/sec-form-3-filed-by-c-david-sachs-503151)
- 2021-03-12 02:47 UTC [SEC Form 3] [SEC Form 3 filed by Owen John Brennan](https://www.quantisnow.com/insight/sec-form-3-filed-by-owen-john-brennan-503150)
- 2021-03-12 02:48 UTC [SEC Form 3] [SEC Form 3 filed by Wesley Clark](https://www.quantisnow.com/insight/sec-form-3-filed-by-wesley-clark-503149)
- 2021-03-12 02:30 UTC [SEC Form 4] [SEC Form 4: Patrick Soon-Shiong increased direct ownership by 24% to 29,473,932 units](https://www.quantisnow.com/insight/sec-form-4-patrick-soon-shiong-increased-direct-ownership-by-24-503128)
- 2021-03-10 02:58 UTC [SEC Form 8-K filed](https://www.quantisnow.com/insight/sec-form-8-k-filed-492758)
- 2021-03-09 21:15 UTC [ImmunityBio and NantKwest Complete Merger](https://www.quantisnow.com/insight/immunitybio-and-nantkwest-complete-merger-490495)
- 2021-03-08 21:50 UTC [SEC Form 425 filed](https://www.quantisnow.com/insight/sec-form-425-filed-485063)
- 2021-03-08 21:30 UTC [Stockholders of NantKwest Approve Merger With ImmunityBio](https://www.quantisnow.com/insight/stockholders-of-nantkwest-approve-merger-with-immunitybio-484815)
- 2021-03-08 14:00 UTC [ImmunityBio and NantKwest Begin Dosing Participants in Global Trials for Novel COVID-19 Vaccine; Subcutaneous Route in South Africa, Oral and Sublingual in the U.S.](https://www.quantisnow.com/insight/immunitybio-and-nantkwest-begin-dosing-participants-in-global-trials-for-482936)
- 2021-03-04 21:11 UTC [SEC Form 10-K filed](https://www.quantisnow.com/insight/sec-form-10-k-filed-474532)
- 2021-03-02 21:44 UTC [SEC Form 425 filed](https://www.quantisnow.com/insight/sec-form-425-filed-461314)
- 2021-02-25 22:17 UTC [SEC Form 425 filed](https://www.quantisnow.com/insight/sec-form-425-filed-442790)
- 2021-02-25 22:15 UTC [SEC Form 8-K filed](https://www.quantisnow.com/insight/sec-form-8-k-filed-442749)
- 2021-02-25 00:26 UTC [All Three Independent Proxy Advisory Firms – ISS, Glass Lewis and Egan-Jones – Recommend NantKwest Stockholders Vote “FOR” the Pending Merger With ImmunityBio](https://www.quantisnow.com/insight/all-three-independent-proxy-advisory-firms-iss-glass-lewis-and-430424)
- 2021-02-24 22:02 UTC [SEC Form 425 filed](https://www.quantisnow.com/insight/sec-form-425-filed-429779)
- 2021-02-24 21:59 UTC [SEC Form 8-K filed](https://www.quantisnow.com/insight/sec-form-8-k-filed-429775)
- 2021-02-24 14:00 UTC [Leadership Update] [ImmunityBio Appoints John Brennan and Wesley Clark to Board of Directors ](https://www.quantisnow.com/insight/immunitybio-appoints-john-brennan-and-wesley-clark-to-board-of-427384)
- 2021-02-11 23:13 UTC [ImmunityBio and NantKwest Announce FDA Authorization to Study hAd5 T-Cell COVID-19 Vaccine for Combination of Subcutaneous, Oral and Sublingual Boost to Induce T-Cell, Mucosal, and Antibody Immunity](https://www.quantisnow.com/insight/immunitybio-and-nantkwest-announce-fda-authorization-to-study-had5-t-cell-386188)
- 2021-02-10 21:38 UTC [SEC Form 8-K filed](https://www.quantisnow.com/insight/sec-form-8-k-filed-378910)
- 2021-02-10 02:47 UTC [SEC Form 4] [SEC Form 4: Richard Adcock exercised 150,000 units of Common Stock at a strike of $0.00 and disposed of $1,617,016 worth of Common Stock (68,171 units at $23.72)](https://www.quantisnow.com/insight/sec-form-4-richard-adcock-exercised-150000-units-of-common-371896)
- 2021-02-08 21:54 UTC [SEC Form 4] [SEC Form 4: J. Barry Simon sold $510,267 worth of Common Stock (22,100 units at $23.09) and exercised 22,100 units of Common Stock at a strike of $2.00](https://www.quantisnow.com/insight/sec-form-4-j-barry-simon-sold-510267-worth-of-364856)
- 2021-02-04 23:39 UTC [SEC Form 4] [SEC Form 4: J. Barry Simon exercised 82,070 units of Common Stock at a strike of $2.00 and sold $1,694,803 worth of Common Stock (82,070 units at $20.65)](https://www.quantisnow.com/insight/sec-form-4-j-barry-simon-exercised-82070-units-of-355756)
- 2021-02-02 11:10 UTC [SEC Form DEFM14A filed](https://www.quantisnow.com/insight/sec-form-defm14a-filed-338661)
- 2021-02-02 11:05 UTC [SEC Form 424B3 filed](https://www.quantisnow.com/insight/sec-form-424b3-filed-338646)
- 2021-02-02 05:15 UTC [SEC Form EFFECT filed](https://www.quantisnow.com/insight/sec-form-effect-filed-338635)
- 2021-01-30 00:59 UTC [SEC Form 4] [SEC Form 4: J. Barry Simon exercised 47,930 units of Common Stock at a strike of $2.00 and sold $987,067 worth of Common Stock (47,930 units at $20.59)](https://www.quantisnow.com/insight/sec-form-4-j-barry-simon-exercised-47930-units-of-332148)
- 2021-01-29 22:01 UTC [SEC Form S-4/A filed](https://www.quantisnow.com/insight/sec-form-s-4a-filed-331392)
- 2021-01-28 14:00 UTC [ImmunityBio Announces Positive Phase 2 Results Showing That Anktiva Restores the Activity of Checkpoint Inhibitors in Patients Who Have Relapsed Checkpoint Immunotherapy in Non-Small Cell Lung Cancer](https://www.quantisnow.com/insight/immunitybio-announces-positive-phase-2-results-showing-that-anktiva-restores-324649)
- 2021-01-19 22:20 UTC [SEC Form S-4 filed](https://www.quantisnow.com/insight/sec-form-s-4-filed-295933)
- 2021-01-19 13:00 UTC [ImmunityBio Simulations Reveal Why the New Strain of SARS-CoV-2 in South Africa is Spreading Fast and May ‘Escape’ Existing Immunity](https://www.quantisnow.com/insight/immunitybio-simulations-reveal-why-the-new-strain-of-sars-cov-2-in-292923)
- 2021-01-15 13:00 UTC [CytRx Highlights Use of Aldoxorubicin in Phase 2 Clinical Trials Yielding Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Patients](https://www.quantisnow.com/insight/cytrx-highlights-use-of-aldoxorubicin-in-phase-2-clinical-trials-287679)
- 2021-01-13 23:01 UTC [NantKwest, ImmunityBio Announce Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Trials](https://www.quantisnow.com/insight/nantkwest-immunitybio-announce-positive-interim-data-on-survival-rates-in-282804)
- 2021-01-13 22:11 UTC [SEC Form 425 filed](https://www.quantisnow.com/insight/sec-form-425-filed-282666)
- 2021-01-13 21:19 UTC [SEC Form 4: Sonja Nelson exercised 11,364 units of Common Stock at a strike of $3.07 and sold $245,460 worth of Common Stock (16,364 units at $15.00), decreasing ownership by 24% to 15,410 units](https://www.quantisnow.com/insight/sec-form-4-sonja-nelson-exercised-11364-units-of-common-282391)
- 2021-01-13 14:17 UTC [SEC Form 8-K filed](https://www.quantisnow.com/insight/sec-form-8-k-filed-281050)
- 2021-01-12 12:00 UTC [iosBio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro™ oral vaccine platform technology for COVID-19  ](https://www.quantisnow.com/insight/iosbio-signs-exclusive-worldwide-licensing-agreement-granting-immunitybio-rights-to-275679)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/NK
- Earnings history: https://www.quantisnow.com/earnings/NK
- Dividend history: https://www.quantisnow.com/dividends/NK
- Insider transactions: https://www.quantisnow.com/insiders/NK
- Options chain: https://www.quantisnow.com/options/NK
- SEC 8-K filings only: https://www.quantisnow.com/company/NK/8-k
- RSS and alerts for NK: https://www.quantisnow.com/docs/rss-feeds.md